EDIT
Price
$10.61
Change
-$0.01 (-0.09%)
Updated
Nov 30, 3:01 PM EST
84 days until earnings call
LYEL
Price
$1.69
Change
+$0.02 (+1.20%)
Updated
Nov 30, 2:27 PM EST
117 days until earnings call
Ad is loading...

Compare trend and price EDIT vs LYEL

Header iconEDIT vs LYEL Comparison
Open Charts EDIT vs LYELBanner chart's image
Editas Medicine
Price$10.61
Change-$0.01 (-0.09%)
Volume$1.27K
CapitalizationN/A
Lyell Immunopharma
Price$1.69
Change+$0.02 (+1.20%)
Volume$100
CapitalizationN/A
View a ticker or compare two or three
EDIT vs LYEL Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
EDIT vs. LYEL commentary
Nov 30, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Buy and LYEL is a Hold.

COMPARISON
Comparison
Nov 30, 2023
Stock price -- (EDIT: $10.61 vs. LYEL: $1.67)
Brand notoriety: EDIT and LYEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 100% vs. LYEL: 99%
Market capitalization -- EDIT: $870.23M vs. LYEL: $395.43M
EDIT [@Biotechnology] is valued at $870.23M. LYEL’s [@Biotechnology] market capitalization is $395.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileLYEL’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • LYEL’s FA Score: 1 green, 4 red.
According to our system of comparison, EDIT is a better buy in the long-term than LYEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 6 TA indicator(s) are bullish while LYEL’s TA Score has 4 bullish TA indicator(s).

  • EDIT’s TA Score: 6 bullish, 4 bearish.
  • LYEL’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than LYEL.

Price Growth

EDIT (@Biotechnology) experienced а +1.14% price change this week, while LYEL (@Biotechnology) price change was -3.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.53%. For the same industry, the average monthly price growth was +28.79%, and the average quarterly price growth was +21.48%.

Reported Earning Dates

EDIT is expected to report earnings on Feb 22, 2024.

LYEL is expected to report earnings on Mar 26, 2024.

Industries' Descriptions

@Biotechnology (+2.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for EDIT with price predictions.
OPEN
A.I.dvisor published
a Summary for LYEL with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
EDIT($870M) has a higher market cap than LYEL($395M). EDIT YTD gains are higher at: 19.617 vs. LYEL (-51.873). LYEL has higher annual earnings (EBITDA): -182.05M vs. EDIT (-202.49M). LYEL has more cash in the bank: 575M vs. EDIT (350M). EDIT has less debt than LYEL: EDIT (34.6M) vs LYEL (58.6M). LYEL has higher revenues than EDIT: LYEL (48.5M) vs EDIT (24.6M).
EDITLYELEDIT / LYEL
Capitalization870M395M220%
EBITDA-202.49M-182.05M111%
Gain YTD19.617-51.873-38%
P/E RatioN/A3.02-
Revenue24.6M48.5M51%
Total Cash350M575M61%
Total Debt34.6M58.6M59%
FUNDAMENTALS RATINGS
EDIT: Fundamental Ratings
EDIT
OUTLOOK RATING
1..100
22
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
EDITLYEL
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 18 days ago
86%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
67%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NCVLX11.610.02
+0.17%
Nuance Concentrated Value Institutional
MMOAX13.050.02
+0.15%
MassMutual Disciplined Value Y
FASRX10.93N/A
N/A
K2 Alternative Strategies R6
ACAYX35.93-0.05
-0.14%
Alger Capital Appreciation Instl Y
AGYWX50.64-0.07
-0.14%
American Century Growth Y

LYEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYEL has been loosely correlated with DNLI. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if LYEL jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYEL
1D Price
Change %
LYEL100%
+1.83%
DNLI - LYEL
53%
Loosely correlated
+0.38%
NTLA - LYEL
49%
Loosely correlated
+0.59%
ADPT - LYEL
48%
Loosely correlated
+5.72%
MDGL - LYEL
46%
Loosely correlated
+3.36%
AGEN - LYEL
44%
Loosely correlated
-0.50%
More